New drug combo for stomach cancer with HER2
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of targeted therapy (DP303c) with either a drug called simmitinib or a liposomal form of irinotecan for people with advanced stomach or GEJ cancer. The goal is to see if these combinations can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that has gotten worse after at least one round of chemotherapy (with or without immunotherapy).
- Your tumor has a HER2 level of 1+ (for Cohort 2) or 2+ to 3+ (for Cohort 1).
- You have at least one tumor that can be measured on a scan.
- You are not allergic to any part of the study drug, and you do not have serious eye, heart, or nerve problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
This trial is testing a combination of four medicines (RC48, adebrelimab, apatinib, and S-1) as a pre-surgery treatment for people with locally advanced stomach cancer that is HER2 positive. The goal is to shrink the tumor before surgery and possibly improve outcomes.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
Hear when a new Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.